AB-Prevention (717273)

  https://cordis.europa.eu/project/id/717273

  Horizon 2020 (2014-2020)

  Highly efficient and eco-innovative probiotic food supplement for antibiotic-associated disorders prevention

  Resource-efficient eco-innovative food production and processing (SFS-08-2015-1)

  bacteriology  ·  antibiotics  ·  obesity

  2016-03-01 Start Date (YY-MM-DD)

  2016-05-31 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Development of novel probiotic solutions for specific illnesses and health problems, ex: Obesity, Depression, Crohn or Colitis diseases. The solutions proposed by MyBiotics will use Mycrobe TM a delivery technology to overpass the biologic barriers :gastric acid, pancreatic juice and bile salts, and deliver sufficient quantity of living probiotic directly to colonize the gastro intestinal tract were they are therapeutically efficient. MyBiotics will design for each targeted disease a set of specific bacteria and validate their selection by using MycrobeTM as leverage to provide unreached comfort and easy variation during the selection and test of the probiotics. The ambition is to provide pharmabiotic solutions for specific diseases and provide robust clinical results for lobbying activities with the EMA, EFSA and FDA for the regulation

  Complicit Organisations

1 Israeli organisation participates in AB-Prevention.